| HS Code | 927204 |
| Product Name | Gosling Plague Vaccine, Live (Strain GD) Veterinary Grade API |
| Vaccine Type | Live attenuated viral vaccine |
| Virus Strain | GD strain |
| Target Species | Goslings (geese) |
| Indication | Active immunization against gosling plague (goose parvovirus) |
| Administration Route | Subcutaneous or intramuscular injection; oral for some formulations |
| Available Dosage Forms | Tablets, injections, capsules, powders, granules, premix, solutions |
| Veterinary Grade | API for veterinary use |
| Shelf Life | Typically 12–24 months from manufacture date |
| Adjuvant | None or specified according to formulation |
| Preservative | May contain stabilizers or preservatives per formulation |
| Pharmaceutical Form Category | Veterinary biological API |
| Administration Considerations | Avoid use in immunocompromised or stressed birds; consult veterinarian |
As an accredited Gosling Plague Vaccine,Live(Strain GD) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Supplied as lyophilized live vaccine in sealed glass vials, 100 doses per vial, for veterinary pharmaceutical formulation. |
| Container Loading (20′ FCL) | 20′ FCL container loaded with Gosling Plague Vaccine (Strain GD) veterinary API in various dosage forms for safe transport. |
| Shipping | Shipment of Gosling Plague Vaccine, Live (Strain GD), Veterinary Grade API requires strict cold-chain logistics. Ship in validated insulated containers with refrigerants or dry ice, maintaining recommended temperature throughout transit. Include temperature monitors and export documentation. Ensure compliance with veterinary biological regulations, proper biohazard labeling, and secure, tamper-evident packaging to preserve viability. |
| Storage | Store at 2–8°C in a dry, dark, well-ventilated area. Keep in original sealed container, protected from moisture, heat, and direct sunlight. Do not freeze. Avoid exposure to oxidizing agents. Ensure strict cold-chain maintenance during transport. Once opened, use immediately; discard unused remainder per veterinary biological waste guidelines. |
| Shelf Life | Shelf Life: 24 months from manufacture when stored at 2–8°C, protected from light, in unopened, intact containers. |
Within hatchery-level vaccination programmes for domestic goose and Muscovy duck production, clarified bulk harvests of Gosling Plague Vaccine, Live (Strain GD) are converted into lyophilized injection-grade vaccine through a sequence of stabilizer addition, aseptic filling, and low-temperature desiccation. The stabilizer system for injectable presentation is typically based on sucrose at 5% w/v, hydrolyzed gelatin at 1.0% w/v, and phosphate buffer at 0.02 M pH 7.2; the final master formulation is defined by the regulatory dossier and differs across manufacturing sites. Blended monovalent bulk is dispensed into Type I borosilicate glass vials conforming to ISO 8362-1:2018 and sealed with chlorobutyl stoppers meeting ISO 8536-2:2020. Freeze-drying is performed with shelf temperatures held below -38 °C during primary drying and chamber pressure maintained between 60 mTorr and 100 mTorr. The lyophilized cake must not exceed 2.0% residual moisture as determined by Karl Fischer titration under USP ⟨921⟩. After reconstitution with sterile diluent, the injection volume for day-old goslings is commonly 0.2–0.5 mL per bird by subcutaneous or intramuscular route. Release titer specifications for live goose parvovirus vaccines are expressed as minimum TCID50 per dose and vary by national monograph; batch-specific certificates from the API supplier remain the controlling reference. Finished-product sterility is verified according to Ph. Eur. 2.6.1, and absence of mycoplasma is tested under Ph. Eur. 2.6.7. Production-scale equipment usually includes a 10–50 L stainless-steel blending vessel, peristaltic filling pumps operating at 120–240 vials/min, and a freeze-dryer with shelf temperature uniformity of ±1.5 °C. The operational boundary is post-reconstitution hold time: once dissolved, the liquid vaccine should be used within 2 hours at 2–8 °C, and residual contents in opened vials are discarded.
Mass administration through drinking water in goose breeding units requires the lyophilized or concentrated liquid API to be diluted through a proportioning pump into dechlorinated mains water. Residual free chlorine is the principal process failure variable; concentrations above 0.2 mg/L reduce live GPV infectivity within 30 minutes at 25 °C. Sodium thiosulfate is therefore added at a stoichiometric ratio of 2.85 mg per 1 mg free chlorine, followed by 10 minutes of mixing before vaccine introduction. Skimmed milk powder at 1.0–2.0 g/L or sodium caseinate at 0.5 g/L is then introduced as a chlorine-demand buffer and protective protein. The preferred delivery equipment is an electric diaphragm metering pump with 1:100 or 1:200 proportioning ratio. Piston-type proportioners operating above 1,500 rpm have been associated with shear-related titer loss in live avian virus suspensions. Water contact materials must be polyethylene or polypropylene; galvanized steel and copper piping are unsuitable because transition-metal ions above 0.1 mg/L can accelerate viral capsid aggregation. Stock water temperature must remain below 15 °C during the drinking window, and the medicated solution must be consumed within 4 hours of preparation. Drinker line velocity should be maintained at 0.5–1.0 m/s to prevent sedimentation of stabilizer-virus complexes in dead legs. Efficacy after drinking-water vaccination is commonly checked at 14 days post-vaccination by serum neutralization or ELISA; published data specific to strain GD seroconversion after this route are limited, so hatchery-level validation against an injectable reference group is required.
For tablet and capsule presentations intended for individual oral delivery to waterfowl, the strain GD API is first diluted with a pre-chilled lyoprotectant matrix such as mannitol, trehalose dihydrate, and glycine before dry blending. The blend is compacted on a rotary tablet press with 8 mm flat-faced tooling pre-conditioned to 15 °C; compression force is restricted to 5–8 kN because higher pressures produce measurable viability loss. Published data for strain GD-specific logarithmic reduction under axial compression are limited, but general live-virus tableting models indicate that pressures exceeding 50 MPa may reduce infectivity by 1–2 log10 TCID50. Because live goose parvovirus has no lipid envelope, dry granulation must avoid frictional heating above 30 °C; roller compaction with chilled rolls operating below 10 °C is preferred over wet granulation. Capsule filling is more compatible with live-virus viability because hard gelatin or hydroxypropyl methylcellulose shells are filled at relative humidity below 20% RH using a tamping-pin or dosator machine. The filled capsule shell functions as a moisture barrier, but the terminal product still requires desiccant packaging and storage at 2–8 °C. Acidic enteric coatings are incompatible; any coating requiring aqueous pH below 4.0 or organic solvent exposure must be avoided because GPV infectivity declines sharply under acidic conditions.
| Dosage conversion | Processing equipment | Critical variable | Validated operational boundary |
|---|---|---|---|
| Lyophilized injectable cake | Shelf freeze-dryer with mapped uniformity ±1.5 °C | Residual moisture by Karl Fischer | ≤2.0% per USP ⟨921⟩ |
| Drinking-water dilution | Electric diaphragm proportioning pump 1:100–1:200 | Free chlorine before stabilizer | ≤0.2 mg/L |
| Tablet compression | Rotary tablet press with chilled 8 mm tooling | Compression force | 5–8 kN |
| Capsule filling | Tamping-pin or dosator capsule filler | Ambient relative humidity | ≤20% RH |
| Coarse-spray cabinet | Rotary atomizer 8,000–12,000 rpm | Droplet volume median diameter | >100 µm |
| Freeze-dried granules | Fluid-bed processor with -40 °C inlet air dew point | Product temperature | ≤30 °C |
High-volume waterfowl hatcheries processing more than 30,000 day-old goslings per day may require coarse-spray administration of strain GD vaccine where individual injection is not operationally feasible. The primary registered parenteral route remains injection, and published efficacy data for GPV strain GD delivered by coarse spray are limited. Where local veterinary approval exists, the lyophilized API is reconstituted at 1.5× the injectable dose per bird to compensate for incomplete preening uptake. Chamber relative humidity is maintained at 60–70% and chamber temperature at 20–25 °C; a holding fan provides air velocity of 0.3–0.5 m/s. The diluent contains 2% w/v gelatin and 0.05% w/v nonionic surfactant to reduce nozzle coalescence. The vaccine suspension is transferred to a rotary atomizer spinning at 8,000–12,000 rpm, with droplet volume median diameter maintained above 100 µm to limit entry into the lower respiratory tract. The nozzle system must be sterilized by autoclaving before use, and the holding tank must be continuously chilled to 4 °C. After 45 minutes in the holding tank, virus titers begin to decline unless the suspension is continuously cooled. The main process conflict is the narrow window between droplet size sufficient for preening uptake and droplet size small enough to enter the respiratory tract; this window must be confirmed by laser diffraction on the actual cabinet nozzle before field use.
Dry premix and granule delivery for live strain GD is constrained by the incompatibility of live parvovirus with steam pelleting and prolonged ambient storage. Water-soluble granules are produced by spray-freezing the API with a protective carbohydrate matrix, followed by air drying at 35 °C for 2 hours. Granulation is performed in a fluidized-bed processor with inlet air dew point below -40 °C and product temperature below 30 °C. The resulting granule size range must remain between 0.250 mm and 0.850 mm to ensure rapid reconstitution in water. If the granules are incorporated into a dry premix with lactose, the lactose monohydrate must be low in reducing sugar impurities because Maillard reaction products can destabilize the viral capsid. The granules are packed in foil-lined sachets with an oxygen scavenger and used as a water-dispersible stock rather than a feed ingredient. Published data for strain GD long-term stability in granular form are limited; non-sterile granules cannot be terminally sterilized, so this presentation is restricted to veterinary prescription use under direct field supervision.
Third-party fill-finish operations receiving strain GD API in bulk require defined acceptance limits before downstream processing can proceed. The incoming API must be accompanied by a batch certificate stating infectious titer, residual moisture, sterility, mycoplasma status, and identity confirmation by virus-specific PCR or monoclonal antibody assay. Bulk lyophilized API is stored at -20 °C or below during international transfer; dry ice packaged containers must maintain internal temperature below -15 °C for 72 hours minimum transit time. Upon receipt, the fill-finish site performs an identity check and a titer verification on a statistically defined sample according to the site’s validated sampling plan. The API is then reconstituted under aseptic conditions, blended with the site-specific stabilizer, and filled into multidose vials. Filling line speed is typically limited to 80–120 vials/min to avoid excessive frothing and viral shear. Filter compatibility must be confirmed because live parvovirus adsorbs to certain membrane polymers; low-protein-binding membranes are used for any filtration step. The final filled product is visually inspected for cake collapse, meltback, and container-closure defects before labeling and cold-chain distribution. This fill-finish interface is governed by national veterinary biological product regulations and the importing country’s good manufacturing practice requirements for veterinary immunologics; exact release titers and stability profiles remain specific to the authorized dossier in each jurisdiction.
Competitive Gosling Plague Vaccine,Live(Strain GD) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
The product designated Gosling Plague Vaccine, Live (Strain GD) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a live attenuated goose parvovirus antigen concentrate supplied for further manufacture into finished immunological veterinary medicinal products. The model identifier Strain GD defines the attenuated master seed lineage; release identity is confirmed by virus-specific nucleic acid amplification or immunofluorescence against the manufacturer’s reference preparation. The API is not a ready-to-administer vaccine. It is presented as a frozen liquid or lyophilized cake and requires formulation, filling, labelling, and batch certification by a licensed veterinary biologics manufacturer. The active fraction is non-enveloped and belongs to the parvovirus group; it is susceptible to strong oxidizing disinfectants, formaldehyde, beta-propiolactone, and thermal abuse. Its non-enveloped nature confers relative resistance to organic solvents such as ether or chloroform, but this does not permit solvent exposure in finished dosage forms.
The API may be incorporated into tablets, injections, capsules, powders, granules, premix, or solutions. The choice of form determines route, stabilizer system, critical process parameters, and cold-chain intensity. Tablets and capsules are non-conventional presentations for live avian vaccines and require direct compression with protective matrices rather than aqueous granulation; injections and solutions require aseptic buffered vehicles; dry powders, granules, and premix require low-humidity blending and moisture-barrier packaging. Virus titer, residual moisture, and water activity are therefore release-critical, not merely stability indicators.
Each batch is released against identity, virus titer, sterility, mycoplasma absence, extraneous agent exclusion, residual moisture, endotoxin, pH, appearance, and where applicable residual solvent or antibiotic marker content. Quantitative acceptance limits are established by the manufacturer from process validation and stability data; the table identifies the control principle rather than a universal numerical value. Virus titer is expressed as a median tissue culture infectious dose or median egg infectious dose per gram or per millilitre; the 95% confidence interval of such assays is commonly 0.3–0.5 log10, so blending calculations include a potency allowance for assay variability and end-of-shelf-life loss.
| Quality attribute | Reference method or standard | Release control principle |
|---|---|---|
| Identity | Virus-specific PCR / immunofluorescence | Match to GD master seed and working seed references |
| Virus titer | TCID50 or EID50 assay | Manufacturer-defined minimum per gram or per millilitre |
| Sterility | USP <71> | No growth in fluid thioglycollate medium or soybean-casein digest medium at specified incubation temperatures |
| Mycoplasma | Ph. Eur. 2.6.7 | Absence in broth and indicator cell culture |
| Extraneous agents | 9 CFR 113.28 | No cytopathic, hemadsorbing, or fluorescent antibody evidence of extraneous viral agents |
| Residual moisture | USP <921> | Upper limit on certificate; commonly not more than 2.5% w/w for lyophilized live viral material |
| Endotoxin | Ph. Eur. 2.6.14 | Limit scaled to intended maximum dose |
| pH | Ph. Eur. 2.2.3 | Range defined for reconstituted or liquid API |
Manufacture is conducted under GMP for veterinary medicinal products; aseptic operations occur in cleanrooms meeting ISO 14644-1 class ISO 5 at rest. The master seed and working seed lots are maintained in a segregated seed bank; the working seed is tested for purity, identity, and attenuation stability before use in production. Residual moisture is not merely a release attribute. In lyophilized live viral API, moisture below the collapse-related threshold maintains the amorphous stabilizer matrix in a glassy state. When residual moisture rises above the manufacturer’s upper limit, molecular mobility increases, surface protein unfolding accelerates, and infectious titer can decline below the labelled minimum before the end of shelf-life. Lyophilizer shelf mapping is therefore part of process qualification; shelf temperature variation exceeding ±1.0°C across the load can generate cakes with variable moisture and titer, and such variation must be corrected by load-pattern adjustment or cycle redesign. Container closure integrity is tested by dye ingress or vacuum decay according to USP <1207>.
Dry powder, granule, premix, tablet, and capsule formats require milling or sieving of the lyophilized cake, blending with excipients, and filling or compression. These unit operations generate frictional heat, shear, and humidity. A low-shear tumble mixer with jacketed temperature control is preferred over a high-shear granulator; if a tablet press is used, compression force, turret speed, and dwell time must be limited because compaction energy can reduce infectivity. The lyophilized cake is milled through a screen of not less than 0.5 mm under temperature control; a conical mill or oscillating sieve is used rather than a hammer mill because the latter generates more frictional heat. Direct compression with a protective soluble matrix is more compatible than wet granulation with aqueous binder, because the moisture and drying steps in wet granulation may irreversibly damage the live virus. For granules and premix, the API is dry-blended with a carrier such as lactose monohydrate or dextran and filled into sachets or bulk containers under low-humidity conditions. Blending validation includes stratified thief sampling and virus titer determination at multiple locations; acceptance criteria are defined in the process validation protocol rather than assumed from small-scale mixing studies. If ambient relative humidity exceeds 60% RH, handling time should be shortened or controlled at ≤30% RH, because live viral powders absorb water and approach the residual moisture limit rapidly. Suites are commonly held at 18–22°C and ≤35% RH; excursions beyond 25°C or 40% RH require real-time titer monitoring or process validation data.
For lyophilized live viral powders, water activity, not only total moisture, governs amorphous matrix stability. Water activity measured at 25°C below 0.3 is a common operational target for dry blends, because higher water activity increases molecular mobility and destabilizes the viral capsid. Excipient selection must account for water activity and hygroscopicity; microcrystalline cellulose, croscarmellose sodium, and polyvinylpyrrolidone can raise water activity and should be evaluated in binary compatibility studies. Packaging is part of the stability system: moisture-barrier blister cavities, glass vials with bromobutyl stoppers, or aluminium-lined sachets are used when required, and desiccant or oxygen scavenger inclusion is based on real-time stability data. The glass transition temperature of the stabilizer matrix falls as moisture increases; if it drops below storage temperature, cake collapse and accelerated titer loss occur. For capsules, hard gelatin or HPMC capsules can be used, but gelatin capsules require low water activity to avoid cross-linking and moisture transfer. For tablets, compression force is monitored by instrumented punches; a hardness range of 20–40 N is commonly used for rapidly disintegrating oral tablets, but for live virus the acceptable hardness is determined by titer-retention data rather than conventional disintegration performance alone.
Injectable solutions, oral solutions, and liquid premix formats present a separate constraint set. Live GD antigen is diluted into a buffered vehicle that must maintain pH, ionic strength, and cold-chain integrity from bulk filling through administration. The vehicle may contain stabilizers such as hydrolyzed gelatin, sucrose, sorbitol, or recombinant human serum albumin; if hydrolyzed gelatin is used, a concentration of 1.0–2.0% w/w is common but the exact value is formulation-specific. The aqueous vehicle for injectable products is commonly adjusted to an osmolality of 280–320 mOsm/kg and a pH of 6.5–7.8; excursions beyond this range require titer-retention data. Phosphate-buffered saline is acceptable when water quality is controlled, but phosphate may precipitate if calcium or magnesium ions are present in hard water used for drinking-water premix. Therefore, premix vehicles require deionized or softened water to avoid cation-mediated precipitation and pH drift. Free chlorine in municipal water at concentrations of 0.5–1.0 mg/L can reduce live virus titer; oxidative disinfectants must be neutralized, or water must be treated before the live antigen is added. Once reconstituted, the working dilution is commonly held at 2–8°C and used within 2–4 hours unless the manufacturer has validated longer hold times.
The live GD API differs from inactivated whole-virus GPV antigen in replication competence, cold-chain dependence, and route-specific behaviour. Inactivated antigen does not replicate and therefore requires higher antigen mass or adjuvant-driven immunostimulation; it is less sensitive to ambient temperature but cannot mimic the mucosal replication phase of live virus. Live GD strain can induce secretory IgA and cell-mediated responses after oral or intramuscular administration; however, it is subject to maternal antibody neutralization in young goslings. Recombinant VP2 subunit vaccines express only the major capsid protein and are non-infectious, which removes reversion risk but may require strong adjuvants and multiple injections. The GD strain is distinct from other live attenuated GPV strains because its attenuation markers and passage history are defined in the master seed. Cross-strain substitution should not be assumed; a change in master seed identity or passage level requires a new immunogenicity and safety file. Inactivated GPV antigen is often formulated as an oil-emulsion injectable product; live GD API is suitable for oral or mucosal formulations in addition to injectable presentations.
The live GD API is incompatible with formaldehyde, beta-propiolactone, strong oxidizing sterilants, and chlorine-releasing agents. Equipment sanitized with these agents must be rinsed with sterile water and verified free of residual disinfectant before contact with the antigen. Quaternary ammonium compounds are not reliable virucidal agents against non-enveloped parvoviruses and must not be used as the sole disinfectant for containment or sanitization of live antigen contact surfaces. The API should be stored at the temperature stated on the certificate, typically −20°C or 2–8°C depending on presentation; repeated freeze-thaw cycles are not acceptable unless stability data support them. Batches should be traced by seed lot, harvest date, and freeze-dryer load. If published data for a particular dosage form is limited, compatibility under the selected manufacturing process must be demonstrated by titer retention studies in the target container-closure system. The API is for veterinary use only and must be handled under the receiving country’s veterinary biologics regulations, including 9 CFR 101–118 in the United States or Regulation (EU) 2019/6 in the European Union where applicable.
